Abstract
Background In the UK, around one-third of young people are exposed to IPVA by 21 years old. However, types of IPVA victimisation in this population (psychological, physical, sexual), and their relationship with impact and perpetration are poorly understood.
Methods Participants in a UK birth cohort reported IPVA victimisation and perpetration by age 21. We carried out a latent class analysis, where we categorised IPVA by types/frequency of victimisation, and then assigned individuals to their most probable class. Within these classes, we then estimated risks of reported: 1) types of negative impacts (sad, upset/unhappy, anxious, depressed, affected work/studies, angry/annoyed, drank/took drugs more); 2) types/frequency of perpetration.
Results Among 2,130 women and 1,149 men, 32% and 24% reported IPVA victimisation (of which 89% and 73% reported negative impact); 21% and 16% perpetration. Victimisation responses were well represented by five classes, including three apparent in both sexes: No-low victimisation (characterised by low probabilities of all types of victimisation; average probabilities of women and men belonging to this class were 82% and 70%); Mainly psychological (15% and 12%); Psychological & physical victimisation (4% and 7%), and two classes that were specific to women: Psychological & sexual (7%); Multi-victimisation (frequent victimisation for all three types; 4%). In women, all types of negative impact were most common in the Psychological & sexual and Multi-victimisation classes; for men, the Psychological & physical class. In women, all types of perpetration were most common for the Mainly psychological, Psychological & physical, and Multi-victimisation classes; in men, the Mainly psychological and Psychological & physical classes.
Discussion In this study of young people, we found categories of co-occurrence of types and frequency of IPVA victimisation associated with differential risks of negative impact and perpetrating IPVA. This is consistent with emerging evidence of IPVA differentiation and its variable impact in other populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The UK Medical Research Council (MRC) and Wellcome (ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); the inclusion of questions on IPVA within the age 21 questionnaire was funded by NHS Bristol Clinical Commissioning Group (ref: RP-PG-0108-10048; PI: GF). This research was specifically funded an MRC grant (ref: MR/S002634/1). AF and LDH are funded by MRC personal fellowships (refs: MR/M009351/1, MR/M020894/1). AH, JH, LDH, and AF work in a unit that receives funding from the University of Bristol and the MRC (ref: MC_UU_12013/2).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Full details of the ALSPAC consent procedures are available on the study website (http://www.bristol.ac.uk/alspac/researchers/research-ethics/). The questions on IPVA were approved by the ALSPAC Ethics and Law Committee (ref: E201210).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos